Toxicology – Benzocaine

Core concept

Benzocaine is an ester local anesthetic that can cause acquired methemoglobinemia.

The hallmark toxicity is:

Benzocaine exposure → oxidation of hemoglobin Fe²⁺ to Fe³⁺ → methemoglobinemia → impaired oxygen delivery → tissue hypoxia

A characteristic presentation is:

Cyanosis that does not improve adequately with oxygen + relatively normal PaO₂ + chocolate-brown blood

Forms and Uses

Benzocaine is found in numerous topical preparations, including:

• Oral gels and liquids
• Toothache preparations
• Throat sprays and lozenges
• Topical creams and ointments
• Aerosol anesthetic sprays
• Otic preparations
• Hemorrhoidal preparations

It may also occasionally be encountered as an adulterant in illicit drugs.

Pediatric Warning

Infants and young children are particularly susceptible to benzocaine-induced methemoglobinemia.

The FDA advises that benzocaine-containing oral products should not be used in children younger than 2 years, particularly for teething pain. Benzocaine provides little benefit for teething and can cause potentially fatal methemoglobinemia.

Toxic Dose

There is no reliably safe dose that excludes methemoglobinemia.

Toxicity has occurred:

• After overdose
• After repeated topical application
• After excessive mucosal application
• Occasionally after apparently therapeutic use

The older source reports toxicity in infants after ingestion of only 1–2 mL of 7.5% benzocaine gel.

Susceptibility varies considerably among individuals.

Pathophysiology

Benzocaine is metabolized to oxidizing metabolites capable of converting normal hemoglobin iron:

Fe²⁺ → Fe³⁺

This produces methemoglobin, which cannot effectively bind and transport oxygen.

Normally:

Methemoglobin → reduced back to functional hemoglobin primarily by cytochrome-b5 reductase

When oxidation overwhelms the body’s reducing capacity:

Methemoglobin accumulates → functional anemia + impaired tissue oxygen delivery

Remaining normal hemoglobin also holds oxygen more tightly, further reducing oxygen delivery to tissues.

Risk Factors

Greater susceptibility occurs in:

• Infants, particularly <6 months
• Excessive or repeated benzocaine application
• Application to damaged or highly vascular mucosa
• Anemia
• Significant cardiac disease
• Significant pulmonary disease
• Concurrent oxidizing medications or chemicals
• Congenital methemoglobin-reduction disorders

Young infants have lower methemoglobin-reductase activity and therefore greater susceptibility.

Clinical Features

Symptoms result primarily from functional hypoxia.

Characteristic finding

Central cyanosis despite supplemental oxygen

The skin, lips, and nail beds may appear:

• Blue
• Gray
• Slate-colored

Approximate Severity by Methemoglobin Level

Clinical effects vary, but approximate patterns are:

• <10%: usually asymptomatic
• 10–20%: cyanosis may become apparent
• 20–30%: headache, fatigue, dyspnea, lightheadedness
• 30–50%: tachycardia, confusion, weakness, worsening dyspnea
• 50–70%: severe CNS and cardiovascular toxicity, seizures, dysrhythmias, coma
• >70%: often life-threatening or fatal

Symptoms may occur at lower levels in patients with anemia or significant heart/lung disease.

Cardiovascular

Significant methemoglobinemia may cause:

• Tachycardia
• Hypotension
• Dysrhythmias
• Myocardial ischemia
• Cardiovascular collapse

Pulmonary

Possible manifestations include:

• Dyspnea
• Tachypnea
• Subjective air hunger
• Cyanosis

The problem is impaired oxygen carriage, not necessarily failure of oxygen to enter the lungs.

Neurologic

Progressive hypoxia may cause:

• Headache
• Dizziness
• Anxiety
• Confusion
• Altered mental status
• Seizures
• Coma

Gastrointestinal

• Nausea
• Vomiting

Metabolic

Severe tissue hypoxia may produce:

Lactic acidosis

Dermatologic

Topical benzocaine can also cause:

• Local irritation
• Rash
• Contact hypersensitivity

Diagnosis

The definitive diagnostic test is:

Blood methemoglobin concentration measured by co-oximetry

Normal methemoglobin is generally <1–2%, although laboratory reference ranges vary.

The Classic Diagnostic Clues

1. Cyanosis resistant to oxygen

The patient remains cyanotic despite adequate supplemental oxygen.

2. Chocolate-brown blood

Blood may appear:

Dark chocolate brown

and does not become normally bright red after exposure to oxygen.

3. Normal PaO₂ despite apparent hypoxia

A crucial point:

PaO₂ measures dissolved oxygen in plasma, not oxygen carried by hemoglobin.

Therefore, a patient may have:

• Normal or high PaO₂
• Severe tissue hypoxia from methemoglobinemia

4. Pulse oximetry may be misleading

Standard pulse oximetry cannot accurately quantify methemoglobinemia.

As methemoglobin increases, SpO₂ often trends toward approximately 85%, regardless of the true degree of oxygenation.

Thus:

A normal or near-normal pulse oximeter reading does not reliably exclude clinically important methemoglobinemia.

Saturation Gap

A useful clue is a discrepancy between:

• Pulse oximeter saturation
• Calculated oxygen saturation obtained from an arterial blood gas

This is sometimes called a saturation gap.

Co-oximetry is required for definitive measurement.

Investigations

For symptomatic patients consider:

• Co-oximetry with methemoglobin level
• Blood gas
• Serum electrolytes
• Bicarbonate
• BUN
• Creatinine
• Lactate
• ECG
• Continuous cardiac monitoring

Consider CBC if anemia or hemolysis is suspected.

Benzocaine Levels

Blood or urine benzocaine concentrations are generally not clinically useful for acute management.

Treatment is guided by:

• Clinical condition
• Methemoglobin level
• Evidence of tissue hypoxia

Differential Diagnosis

Other causes of acquired methemoglobinemia include:

• Dapsone
• Nitrites and nitrates
• Aniline compounds
• Phenazopyridine
• Primaquine
• Sulfonamides
• Chlorates
• Naphthalene
• Some local anesthetics

Other causes of cyanosis should also be considered.

Sulfhemoglobinemia

Sulfhemoglobinemia may resemble methemoglobinemia clinically.

Consider it particularly when:

• Cyanosis persists
• Co-oximetry findings are atypical
• There is poor or absent response to methylene blue

Treatment

1. Stop Benzocaine Exposure

Immediately discontinue the offending product.

For dermal exposure:

• Remove contaminated material
• Wash the skin thoroughly with soap and water

For mucosal exposure:

• Remove residual product when practical

2. Oxygen

Administer high-concentration oxygen to symptomatic patients.

Oxygen does not directly convert methemoglobin back to normal hemoglobin, but it maximizes:

• Oxygen carried by remaining functional hemoglobin
• Dissolved plasma oxygen

while definitive treatment is initiated.

3. Methylene Blue

Methylene blue is the primary antidotal treatment for clinically significant acquired methemoglobinemia.

Treatment is based primarily on the patient’s clinical status, not solely on a numerical methemoglobin concentration.

Consider treatment for:

• Neurologic symptoms
• Dyspnea or significant respiratory distress
• Chest pain
• Hypotension
• Significant acidosis
• Other evidence of tissue hypoxia

Treatment is also commonly considered when methemoglobin concentrations are approximately 20–30% or greater, with a lower threshold in patients with:

• Significant anemia
• Cardiovascular disease
• Pulmonary disease

Dose

Methylene blue 1–2 mg/kg IV over approximately 5 minutes

A clinical response usually occurs rapidly.

If significant symptoms or methemoglobinemia persist, the dose may be repeated after approximately 30–60 minutes.

Mechanism of Methylene Blue

Methylene blue is reduced to leukomethylene blue through an NADPH-dependent pathway.

Leukomethylene blue then reduces:

Fe³⁺ methemoglobin → Fe²⁺ functional hemoglobin

G6PD Deficiency

Methylene blue requires adequate NADPH production.

In G6PD deficiency:

• Response to methylene blue may be inadequate
• Methylene blue can precipitate or worsen hemolysis

Therefore, significant known G6PD deficiency requires specialist toxicology/hematology input and consideration of alternative treatment.

Importantly, treatment of a critically hypoxic patient should not necessarily be delayed while waiting for a G6PD test result.

Excessive Methylene Blue

Large cumulative doses may paradoxically act as an oxidizing agent and can:

• Worsen methemoglobinemia
• Produce hemolysis

The risk rises with excessive cumulative dosing.

Serotonin Syndrome

Methylene blue also inhibits monoamine oxidase-A.

Therefore, patients taking serotonergic drugs may be at risk of serotonin toxicity when methylene blue is administered.

In severe, life-threatening methemoglobinemia, treatment decisions must balance this risk against the immediate danger of tissue hypoxia.

Refractory Methemoglobinemia

If severe methemoglobinemia does not respond adequately to methylene blue, consider specialist-directed therapy such as:

• Exchange transfusion
• Hyperbaric oxygen in selected cases

These approaches are particularly relevant when methylene blue is ineffective or contraindicated.

Ascorbic Acid

Ascorbic acid can reduce methemoglobin but works much more slowly than methylene blue.

It is not the preferred treatment for rapidly progressive, life-threatening methemoglobinemia, but may have a role in selected circumstances when methylene blue cannot be used.

Gastrointestinal Decontamination

Do not induce vomiting

Emesis should not be induced because neurologic deterioration or seizures may occur and aspiration is possible.

Activated Charcoal

Activated charcoal may be considered after a significant recent ingestion when:

• The airway is intact or protected
• Presentation is early
• Aspiration risk is acceptable

Routine gastric lavage is generally not recommended in contemporary poisoning management.

Monitoring

Symptomatic patients should receive:

• Continuous cardiac monitoring
• Pulse oximetry
• Repeated neurologic assessment
• Serial methemoglobin concentrations

After methylene blue:

• Repeat the methemoglobin level
• Monitor clinical response
• Watch for recurrent methemoglobinemia

Rebound Methemoglobinemia

Methemoglobinemia can recur when:

• Benzocaine absorption continues
• A large exposure occurred
• Repeated topical application occurred
• Other oxidizing substances are present

Therefore, clinical improvement after methylene blue does not always eliminate the need for continued observation.

Admission

Hospital admission is appropriate for:

• Symptomatic methemoglobinemia
• Significant elevation of methemoglobin
• Methylene blue treatment
• Hemodynamic instability
• Seizures
• Significant acidosis
• Recurrent methemoglobinemia

Severe cases require ICU-level care.

Prognosis

Most patients recover rapidly when:

• Exposure is stopped
• Methemoglobinemia is recognized early
• Appropriate treatment is given before prolonged tissue hypoxia develops

Poor outcomes may result from:

• Delayed recognition
• Severe prolonged hypoxia
• Seizures
• Cardiovascular collapse
• Significant hemolysis

Important Pitfalls

1. Trusting the PaO₂

A normal PaO₂ does not exclude methemoglobinemia.

PaO₂ reflects dissolved oxygen rather than hemoglobin oxygen-carrying capacity.

2. Trusting pulse oximetry

Pulse oximetry is unreliable for quantifying methemoglobinemia.

Use co-oximetry.

3. Delaying methylene blue in severe symptomatic toxicity

When severe methemoglobinemia is strongly suspected, treatment should not be delayed solely while awaiting confirmatory testing.

4. Missing recurrent toxicity

Methemoglobin levels can rise again after apparently successful treatment.

5. Giving excessive methylene blue

High doses can paradoxically worsen methemoglobinemia and cause hemolysis.

6. Missing G6PD deficiency

Methylene blue may be ineffective and increase hemolysis risk in significant G6PD deficiency.

7. Using benzocaine for infant teething

The FDA advises against benzocaine-containing oral products in children younger than 2 years because of the risk of serious or fatal methemoglobinemia.

High-Yield Toxicology Pearls

Benzocaine = acquired methemoglobinemia

Think:

Benzocaine exposure + cyanosis + chocolate-brown blood + normal PaO₂ → METHEMOGLOBINEMIA

Key points:

• Benzocaine oxidizes hemoglobin Fe²⁺ → Fe³⁺
• Methemoglobin cannot effectively transport oxygen
• Cyanosis may fail to improve with oxygen
• PaO₂ can remain normal
• Standard pulse oximetry is unreliable and often approaches ~85%
• Diagnosis: co-oximetry
• Main antidote: methylene blue
• Dose: 1–2 mg/kg IV over ~5 minutes
• Repeat after 30–60 minutes if clinically necessary
• Methylene blue may cause hemolysis or be ineffective in G6PD deficiency
• Methylene blue can interact with serotonergic medications
• Severe refractory cases may require exchange transfusion or hyperbaric oxygen
• Rebound methemoglobinemia may occur
• Do not use benzocaine oral products for teething in children under 2 years